Longitudinal study based on a safety registry for malaria patients treated with artenimol–piperaquine in six European countries

Longitudinal study based on a safety registry for malaria patients treated with artenimol–piperaquine in six European countries

Abstract Background European travellers to endemic countries are at risk of malaria and may be affected by a different range of co-morbidities than natives of endemic regions. The safety profile, especially cardiac issues, of artenimol (previously dihydroartemisinin)–piperaquine (APQ) Eurartesim® du...

Full description

Bibliographic Details
Main Authors: Nicolas Vignier, Olivier Bouchaud, Andrea Angheben, Emmanuel Bottieau, Guido Calleri, Joaquín Salas-Coronas, Charlotte Martin, José Manuel Ramos, Matthieu Mechain, Christophe Rapp, Hans-Dieter Nothdurft, Maria Velasco, Azucena Bardají, Gerardo Rojo-Marcos, Leo G. Visser, Christoph Hatz, Zeno Bisoffi, Tomas Jelinek, Stephan Duparc, Yann Bourhis, Silva Tommasini, Maurizio Iannucelli, Antonella Bacchieri, Giovan Giuseppe Mattera, Emilio Merlo Pich, Ronald H. Behrens
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Malaria Journal
Subjects:
Imported malaria
Artenimol
Piperaquine
Eurartesim
QTc prolongation
Safety
Online Access:https://doi.org/10.1186/s12936-021-03750-x

Internet

https://doi.org/10.1186/s12936-021-03750-x

Similar Items